<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) are well known complications after chemotherapy for various hematologic and <z:e sem="disease" ids="C0935681" disease_type="Neoplastic Process" abbrv="">non-hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="22333">Alkylating agents</z:chebi> and Topoisomerase inhibitors are most widely studied in this regard </plain></SENT>
<SENT sid="2" pm="."><plain>There is growing concern about occurrence of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in patients of CLL treated with <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues especially in combination with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Exact incidence and pathogenesis of <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogue related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is not clear at this time </plain></SENT>
<SENT sid="4" pm="."><plain>We hereby report a case of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in a patient treated with Fludarabine, <z:chebi fb="0" ids="4027">Cyclophosphamide</z:chebi> and Rituximab (FCR) for CLL </plain></SENT>
<SENT sid="5" pm="."><plain>The cytogenetic studies revealed a unique translocation t (10:16), that has been reported in very few cases of therapy related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="C0220621" disease_type="Neoplastic Process" abbrv="">pediatric AML</z:e> </plain></SENT>
</text></document>